JP6518690B2 - (5,6−ジヒドロ)ピリミド[4,5−e]インドリジン - Google Patents

(5,6−ジヒドロ)ピリミド[4,5−e]インドリジン Download PDF

Info

Publication number
JP6518690B2
JP6518690B2 JP2016560952A JP2016560952A JP6518690B2 JP 6518690 B2 JP6518690 B2 JP 6518690B2 JP 2016560952 A JP2016560952 A JP 2016560952A JP 2016560952 A JP2016560952 A JP 2016560952A JP 6518690 B2 JP6518690 B2 JP 6518690B2
Authority
JP
Japan
Prior art keywords
carboxamide
anilino
dihydropyrimido
indolizine
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016560952A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017510595A (ja
JP2017510595A5 (enExample
Inventor
マン,アドリアヌス ペトルス アントニウス デ
マン,アドリアヌス ペトルス アントニウス デ
クリスティアン ブイスマン,ロジエ
クリスティアン ブイスマン,ロジエ
ゲラルド ステーレンバーグ,ヤン
ゲラルド ステーレンバーグ,ヤン
コルネリス マリヌス ウイッデハーグ,ヨースト
コルネリス マリヌス ウイッデハーグ,ヨースト
ヴィット,ヨエリ ヨハネス ペトルス デ
ヴィット,ヨエリ ヨハネス ペトルス デ
ジェニー ルドルフ ザマン,グイド
ジェニー ルドルフ ザマン,グイド
Original Assignee
ネザーランズ トランスレーショナル リサーチ センター ビー.ブイ.
ネザーランズ トランスレーショナル リサーチ センター ビー.ブイ.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネザーランズ トランスレーショナル リサーチ センター ビー.ブイ., ネザーランズ トランスレーショナル リサーチ センター ビー.ブイ. filed Critical ネザーランズ トランスレーショナル リサーチ センター ビー.ブイ.
Publication of JP2017510595A publication Critical patent/JP2017510595A/ja
Publication of JP2017510595A5 publication Critical patent/JP2017510595A5/ja
Application granted granted Critical
Publication of JP6518690B2 publication Critical patent/JP6518690B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016560952A 2014-04-07 2015-03-30 (5,6−ジヒドロ)ピリミド[4,5−e]インドリジン Active JP6518690B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14163734 2014-04-07
EP14163734.8 2014-04-07
EP15153207 2015-01-30
EP15153207.4 2015-01-30
PCT/EP2015/056839 WO2015155042A1 (en) 2014-04-07 2015-03-30 (5,6-dihydro)pyrimido[4,5-e]indolizines

Publications (3)

Publication Number Publication Date
JP2017510595A JP2017510595A (ja) 2017-04-13
JP2017510595A5 JP2017510595A5 (enExample) 2018-05-17
JP6518690B2 true JP6518690B2 (ja) 2019-05-22

Family

ID=52774240

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016560952A Active JP6518690B2 (ja) 2014-04-07 2015-03-30 (5,6−ジヒドロ)ピリミド[4,5−e]インドリジン

Country Status (16)

Country Link
US (3) US9856258B2 (enExample)
EP (1) EP3129374B1 (enExample)
JP (1) JP6518690B2 (enExample)
KR (1) KR102432420B1 (enExample)
CN (1) CN106132963B (enExample)
AU (1) AU2015243694B2 (enExample)
BR (1) BR112016022342B1 (enExample)
CA (1) CA2944610C (enExample)
DK (1) DK3129374T3 (enExample)
ES (1) ES2716165T3 (enExample)
HU (1) HUE043108T2 (enExample)
MX (1) MX368767B (enExample)
PL (1) PL3129374T3 (enExample)
PT (1) PT3129374T (enExample)
RU (1) RU2692479C2 (enExample)
WO (1) WO2015155042A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015155042A1 (en) * 2014-04-07 2015-10-15 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-e]indolizines
US11208696B2 (en) 2015-04-17 2021-12-28 Netherlands Translational Research Center B.V. Prognostic biomarkers for TTK inhibitor chemotherapy
ES2858753T3 (es) * 2016-02-19 2021-09-30 Phoenix Molecular Designs Derivados de 6-oxo-N-(1-(bencil)-1H-pirazol-4-il)-6,7,8,9-tetrahidropirido[3',2':4,5]pirrolo[1,2-a]pirazin-2-carboxamida como inhibidores de cinasa S6 ribosómica (RSK) p90 para el tratamiento del cáncer
CN109311848B (zh) 2016-06-07 2022-02-01 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
CN106551938B (zh) * 2016-11-26 2017-11-24 广东安诺药业股份有限公司 一种治疗非酒精性脂肪肝的药物及其应用
SMT202400385T1 (it) 2017-03-23 2024-11-15 Jacobio Pharmaceuticals Co Ltd Nuovi derivati eterociclici utili come inibitori di shp2
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
EP3924352A4 (en) 2019-02-11 2022-11-16 Phoenix Molecular Designs CRYSTALLINE FORMS OF AN RSK INHIBITOR
KR20240107189A (ko) * 2021-12-15 2024-07-08 신라젠(주) 신생물성 질환 치료에 사용하기 위한 약제학적 병용물
AU2022408915A1 (en) * 2021-12-15 2024-06-27 Sillajen, Inc. Methods of treating neoplastic diseases
US20250049926A1 (en) * 2021-12-15 2025-02-13 Sillajen, Inc. Pharmaceutical compositions comprising modified betacyclodextrins
AU2023228543A1 (en) * 2022-03-04 2024-08-22 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002337142B2 (en) * 2001-09-19 2007-10-11 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
US7482354B2 (en) 2003-05-22 2009-01-27 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
EP2118102B1 (en) 2006-11-28 2013-06-12 Nerviano Medical Sciences S.r.l. Tricyclic indoles and (4,5-dihydro) indoles
HRP20160243T1 (hr) * 2008-06-26 2016-04-08 Les Laboratoires Servier Pirazolo-kinazolini kao modulatori aktivnosti protein kinaze
WO2010111406A2 (en) 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
CN102428086B (zh) 2009-04-29 2014-08-20 内尔维阿诺医学科学有限公司 Cdk抑制剂的盐类
CN103626777B (zh) 2009-07-29 2015-10-21 内尔维阿诺医学科学有限公司 Plk抑制剂的盐类
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
US20130303532A1 (en) * 2010-12-17 2013-11-14 Bayer Intellectual Property Gmbh Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
BR112013018515B1 (pt) * 2011-01-26 2021-06-29 Nerviano Medical Sciences S.R.I Derivados de pirrol tricíclico, processo para sua preparação e seu uso como inibidores da quinase
JP6523267B2 (ja) 2013-06-24 2019-05-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Fshrの調節剤としてのイミダゾール化合物及びその使用
WO2015155042A1 (en) * 2014-04-07 2015-10-15 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-e]indolizines

Also Published As

Publication number Publication date
KR20170013866A (ko) 2017-02-07
RU2016141405A3 (enExample) 2018-10-02
BR112016022342A8 (pt) 2021-07-20
PT3129374T (pt) 2019-03-25
BR112016022342A2 (pt) 2017-08-15
EP3129374A1 (en) 2017-02-15
MX2016012997A (es) 2016-12-07
RU2692479C2 (ru) 2019-06-25
JP2017510595A (ja) 2017-04-13
DK3129374T3 (en) 2019-04-08
US20170096432A1 (en) 2017-04-06
WO2015155042A1 (en) 2015-10-15
ES2716165T3 (es) 2019-06-10
USRE50082E1 (en) 2024-08-20
CA2944610A1 (en) 2015-10-15
HUE043108T2 (hu) 2019-07-29
AU2015243694B2 (en) 2019-01-17
CN106132963B (zh) 2019-08-06
AU2015243694A1 (en) 2016-11-03
USRE48974E1 (en) 2022-03-15
CN106132963A (zh) 2016-11-16
RU2016141405A (ru) 2018-05-07
CA2944610C (en) 2024-01-09
EP3129374B1 (en) 2018-12-19
KR102432420B1 (ko) 2022-08-17
MX368767B (es) 2019-10-15
PL3129374T3 (pl) 2019-07-31
BR112016022342B1 (pt) 2022-10-04
US9856258B2 (en) 2018-01-02

Similar Documents

Publication Publication Date Title
JP6518690B2 (ja) (5,6−ジヒドロ)ピリミド[4,5−e]インドリジン
AU2020255100B2 (en) N-heteroaromatic amide derivatives for treatment of cancer
KR101238585B1 (ko) 단백질 키나제 억제제로서의 화합물 및 조성물
AU2016352813B2 (en) Novel pyrazolo pyrimidine derivatives
ES2904544T3 (es) Compuestos de indazol como inhibidores de la cinasa FGFR, preparación y uso de los mismos
US9567342B2 (en) Certain protein kinase inhibitors
CA3098574A1 (en) Kras g12c inhibitors and methods of using the same
US20120028924A1 (en) Chemical compounds
WO2005063709A1 (ja) アミド誘導体及び医薬
US20170233395A1 (en) 2,4-disubstituted 7h-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof
JP2025526419A (ja) グルタミニル-ペプチドシクロトランスフェラーゼ及びグルタミニル-ペプチドシクロトランスフェラーゼ様タンパク質の阻害剤としてのピペリジニルピリジニルカルボニトリル誘導体
CA2967551A1 (en) Imidazopyridazine derivatives as pi3k.beta. inhibitors
IL322876A (en) A disintegrant containing an aryl substituent for CDK12/13, a method for its preparation, as well as a pharmaceutical composition and medical use thereof
CN103570731A (zh) 嘧啶并三环或嘧啶并四环类化合物及其药用组合物和应用
HK1231072A1 (en) (5,6-dihydro)pyrimido[4,5-e]indolizines
HK1231072B (zh) (5,6-二氢)嘧啶并[4,5-e]吲嗪
KR20250121126A (ko) Irak3의 리간드 지정 분해제로서의 치환된 이미다조-기재 화합물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180330

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190314

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190409

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190422

R150 Certificate of patent or registration of utility model

Ref document number: 6518690

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250